Background/Aims: Glial cell line-derived neurotrophic factor (GDNF) is an important factor promoting invasive glioma growth. This study was performed to reveal a unique mechanism of glioma cell proliferation and migration. Methods: Human U251 glioma cells were used to screen the optimal GDNF concentration and treatment time to stimulate proliferation and migration. MicroRNA (MiRNA) expression profiles were detected by microarray and confirmed by real-time polymerase chain reaction (PCR). The target genes of differentially expressed miRNAs were predicted by miRWalk, and those targeted by multiple miRNAs were screened with Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. A regulatory miRNA network was constructed using ingenuity pathway analysis (IPA). Target gene expression of differentially expressed miRNAs was examined by real-time PCR or mRNA microarray. Results: The results show that 50 ng/mL GDNF for 24 h significantly promotes U251 glioma cell proliferation and migration (P < 0.05). Seven miRNAs (hsa-miR-194-5p, hsa-miR-152-3p, hsa-miR-205-5p, hsa-miR-629-5p, hsa-miR-3609, hsa-miR-183-5p, and hsa-miR-487b-3p) were significantly up-regulated after GDNF treatment (P < 0.05). These miRNAs are primarily involved in signal transduction, cell adhesion and cell cycle through mitogen-activated protein kinase (MAPK) signaling, focal adhesion and glioma signal pathways. Five of these miRNAs (hsa-miR-194-5p, hsa-miR-152-3p, hsa-miR-205-5p, hsamiR-183-5p, and hsa-miR-487b-3p) co-regulate TP53 and Akt. mRNA expression levels of four genes co-targeted by two or more up-regulated miRNAs were significantly decreased after GDNF treatment (P < 0.05). Conclusion: GDNF treatment of U251 glioma cells significantly increased the expression of seven miRNAs involved in cell adhesion and the cell cycle.
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Introduction
Glioma is the most common malignant primary adult human brain tumor and has one of the lowest survival rates of all cancers [1] . Due to its migratory ability and invasive growth characteristics [2] , disease prognosis remains poor despite advances in neurosurgery, neuroimaging and related technologies. Recent studies have shown that glioma occurrence and development are associated with abnormal expression of many cytokines including glial cell line-derived neurotrophic factor (GDNF) [3] [4] [5] . GDNF is a member of the transforming growth factor beta (TGF-β) super-family that was first isolated and purified in 1993 [6] . GDNF can prolong dopaminergic neuron survival, thus nourishing and protecting populations of peripheral and central neurons including sympathetic, sensory, and motor neurons [7] [8] [9] . GDNF was previously considered as an important pro-differentiation factor with specific physiological roles in development and survival. This hypothesis was challenged by Wiesenhofer and colleagues, who reported abnormally high GDNF expression in primary glioma tissues and multiple glioma cell lines. Notably, the increase positively correlated with pathological tumor grade [10] . Subsequent research revealed that GDNF strongly induces glioma cell proliferation and migration [11] [12] [13] . Knocking down expression of GDNF or its receptor GDNF family receptor α1 (GFRα1) effectively inhibits the pathological progression of glioma [14, 15] . GDNF mainly exerts its functions via the GFRα1/Ret receptor complex [16] . We previously demonstrated that integrin β1, neural cadherin (N-cadherin), and neural cell adhesion molecule (NCAM) adhesion molecules on the cell membrane can act as the signal transduction receptors of GDNF to activate phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) and mitogen-activated protein kinase (MAPK) signaling [17] [18] [19] [20] . Others have shown that downstream factors in these signaling pathways, such as Ki-67, proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 13 (MMP13), and RhoA, significantly promote glioma cell proliferation and migration [11, [21] [22] [23] [24] . The regulatory effects of GDNF on glioma progression involve a complex network with multi-molecule coordination. However, it is still unclear how GDNF achieves multi-molecular regulation through limited receptors to promote glioma cell proliferation and migration.
MicroRNAs (miRNAs) are a class of endogenous genes that encode ~22 nucleotidelong, non-coding, single-stranded RNA molecules that participate in crucial biological processes by imperfectly pairing with target messenger RNAs (mRNAs) of protein-coding genes and transcriptionally or post-transcriptionally regulating their expression [25, 26] . miRNAs can achieve one-to-many or many-to-one patterns to regulate gene expression [27] . Recent studies have shown abnormal miRNA expression in malignant glioma [28, 29] , and these miRNAs can be useful biomarkers [30] . Moreover, some are involved in signaling pathways activated by GDNF, such as c-Jun N terminal kinase (JNK), extracellular signalregulated kinase 1/2 (ERK-1/2), and p38 MAPK signaling pathways, to promote malignant glioma metastasis and invasive growth [31] [32] [33] [34] . Therefore, we hypothesized that high GDNF expression promotes glioma cell proliferation and migration by modulating the expression of specific miRNAs.
We treated human U251 glioma cells with different concentrations of exogenous GDNF for variable times to identify the optimal conditions to promote glioma cell proliferation and migration. miRNA expression levels were measured with microarrays, and the molecular mechanisms of miRNA-mediated, GDNF-promoting glioma cell proliferation and migration were investigated with bioinformatics analysis to predict the functions of differentially expressed miRNAs.
Cell proliferation assay U251 glioma cells were inoculated into 96-well plates at a concentration of 8 × 10 3 cells/well. When cells reached 50% confluence, the culture medium was changed to serum-free DMEM containing 0.5% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO, USA) for incubation for 12 h under the same conditions. Then, the culture medium was replaced with fresh serum-free DMEM containing recombination human GDNF (final concentration of 0, 10, 50, or 100 ng/mL; Gibco/Invitrogen) for an incubation period of 12, 24, 36, or 48 h. The same volumes of phosphate-buffered saline (PBS) were added into control wells. Proliferation was measured using a cell counting kit-8 (Dojindo Molecular Technologies, Kumamoto, Japan) according to the manufacturer's protocol. The absorbance at 450 nm was measured using a microplate reader (Biotek Instruments, Winooski, VT, USA).
U251 glioma cells were seeded in each well of 48-well plate at a concentration of 1.2 × 10 4 cells/well. When cells reached 70% confluence, the culture medium was changed to serum-free DMEM containing 0.5% BSA (Sigma-Aldrich), and the cells were cultured for 12 h under the same conditions. Then the culture medium was replaced with fresh serum-free DMEM containing GDNF (final concentrations of 0, 10, 50 or 100 ng/mL, including 10 μM 5-ethynyl-2′-deoxyuridine [EdU]). After 24 h, cells were fixed with 4% paraformaldehyde for EdU staining, and incubated in 0.5% Triton X-100 in PBS for 10 min at room temperature. Then the cells were incubated in 1 × Apollo® staining reaction liquid for 30 min at room temperature in the dark, and nuclei were stained with 4′, 6-diamidino-2-phenylindole (DAPI, SigmaAldrich). The cells were then examined and photographed with a fluorescence microscope. Red and blue cells were stained with Apollo® and DAPI, respectively.
Cell cycle assay U251 glioma cells were cultured in 60-mm-diameter dishes at a density of (5-8) × 10 5 cells per dish. When cells reached 70% confluence, the culture medium was changed to serum-free DMEM containing 0.5% BSA (Sigma-Aldrich), and cultured for 12 h under identical conditions. Then the culture medium was replaced with fresh serum-free DMEM containing GDNF (final concentration of 0, 10, 50, or 100 ng/mL). After treatment, U251 glioma cells were digested using 0.25% pancreatic enzyme, washed twice with PBS, fixed in precooled 70% (v/v) ethanol overnight, and stained with 100 μg/mL propidium iodide (PI, SigmaAldrich) at 4°C for 30 min. DNA content was monitored with a flow cytometer (FACScan; Becton Dickinson, Franklin Lakes, NJ, USA). Flow cytometry data were analyzed using ModFit LT TM software (Verity Software House, Topsham, ME).
Cell migration and invasion assays U251 glioma cells were inoculated into 12-well plates. When cells reached 100% confluence, scratch wounds were created with a 10-μL pipette tip. The medium was replaced with fresh serum-free DMEM, and cells were cultured for 12 h to ensure that wound healing was due to enhanced migration rather than increased cell proliferation. The culture medium was replaced with fresh serum-free DMEM containing GDNF (final concentration of 0, 10, 50, or 100 ng/mL). Micrographs were taken 0, 12, 24 or 36h after injury. Wound width was measured with Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, MD, USA).
In vitro invasion assays were performed using Costar Transwell inserts (8-mm pore size; Corning, Corning NY,) in 24-well plates. Before performing invasion assays, cells were cultured for 12 h with serumfree DMEM. Approximately 1.3 × 10 4 cells in 100 μL of serum-free medium were placed in the upper chamber, and 600 μL of the same GDNF-containing medium (final concentration of 0, 10, 50, or 100 ng/mL, including 2% FBS) was placed in the lower chamber. The plates were incubated for 36 h at 37°C in 5% CO 2 , then the cells were fixed in 4% paraformaldehyde for 30 min and stained with 1% crystal violet for 20 min. Cells on the upper sides of the filters were removed with cotton-tipped swabs, and the filters were washed with PBS. Cells on the undersides of the filters were examined and counted under a microscope.
Microarray analysis
Total RNAs were extracted using TRIzol reagent (Invitrogen) according to the manufacturer's description and quantified using the NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA). RNA integrity was assessed using standard denaturing agarose gel electrophoresis, purified with the mirVana miRNA Isolation kit (Thermo Fisher Scientific), tailed with polyadenylation polymerase, ligated with biotinylated DNA dendrimers, and hybridized to Affymetrix GeneChip miRNA arrays using the FlashTag [35] . The miRNA and target gene mRNA levels were normalized to the housekeeping gene β-actin.
Cluster analysis
Unsupervised hierarchical clustering was carried out with average linkage and uncentered correlation as the similarity metrics using Cluster 3.0 software [36] . Heatmaps were generated in Java Treeview. Data from each raw probe from the microarrays of all samples were averaged, and then the respective data from the samples were transformed as the provider divided by the average (mean). Relative expression of each miRNA was calculated as the ratio between the sample microarrays and the average of all microarrays [37] . For figure generation, the relative expression of each gene was described as the log 10 (ratio) in the heatmap figures from Cluster 3.0.
Selection of differentially expressed miRNAs and functional analysis
Differentially expressed miRNAs were identified using the significance analysis of microarrays (SAM) program. The miRNAs with a q-value ≤ 0.05 and fold change ≥ 2 or ≤ 0.5 were considered significantly differentially expressed. Using mirWalk, we predicted the target genes and then selected those targeted by two or more significantly differentially expressed miRNAs to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. The -log 10 (P-values) indicating the GO and pathway results were used in the histogram generated with SigmaPlot (Systat Software, Inc., San Jose, CA, USA).
Neutralization studies Native or heat-denatured (5 min at 100°C) anti-GDNF (Abcam, Cambridge, UK) antibody were separately added to complete DMEM. The medium was incubated with the antibody for 15 min at room temperature before it was added to U251 glioma cells to neutralize GDNF. 
Statistical analysis
All data were analyzed with SPSS 16.0 (SPSS, Chicago, IL, USA) and are expressed as mean ± standard deviation (SD). Independent sample t-tests were performed to identify significant differences in the mean values between the two groups. One-way analysis of variance (ANOVA) was used to compare the mean values of multiple samples. P < 0.05 was considered statistically significant.
Results

GDNF significantly enhanced U251 glioma cell proliferation
CCK8 assays were performed to measure U251 glioma cell activity after treatment with different concentrations of GDNF for variable times. After 24 h, GDNF significantly promoted glioma cell activity (P < 0.05) in a dose-dependent manner (Fig. 1A, Table 2 ). EdU staining revealed that 50 and 100 ng/mL GDNF significantly augmented glioma cell proliferation after 24 h treatment (P < 0.01), but there was no significant difference between the two concentrations (P > 0.05) (Fig. 1B, C) . Cell cycle detection showed that 24-treatment with 50 and 100 ng/mL GDNF significantly increased the percentage of cells in S stage (P < 0.05), while the proportion of G1 phase cells declined (P < 0.05). Again, the difference between the two groups was not significant (P > 0.05, Fig. 1D ).
GDNF significantly increased U251 glioma cell migration and invasion
Migration was measured with scratch tests after 12, 24, or 36 h treatment with different concentrations of GDNF. U251 glioma cell migration was significantly enhanced after 24 h incubation with 50 or 100 ng/mL GDNF ( Fig. 2A, C ; Table 3 ). Transwell experiments were performed to investigate U251 glioma cell invasiveness. The results showed that 24-h treatment with 50 or 100 ng/mL GDNF significantly promoted the invasion in a dosedependent fashion (P < 0.01), and the difference between the two groups was significant (P < 0.05) (Fig. 2B, D (Fig. 3A) . The R package Table 3 . Effect of GDNF on cell migration rate of U251 glioma cells. Values are means±SD of five independent experiments. Significant differences among the groups are indicated by different lowercase letters (P < 0.05). Differences among the groups are indicated by different uppercase letters (P < 0.01).
Group
Migrate from SAM was used to screen the differential expression of miRNAs using the following criteria: q-value ≤ 0.05 and fold change ≥ 2 or ≤ 0.5. A total of seven miRNAs (hsa-miR-194-5p, hsa-miR-152-3p, hsa-miR-205-5p, hsa-miR-629-5p, hsa-miR-3609, hsa-miR-183-5p, hsamiR-487b-3p) were differentially expressed, and all seven were up-regulated in response to GDNF stimulation (Table 4) . This is clearly illustrated with a log-log scatter plot (Fig. 3B) . To verify array data reliability, we randomly selected seven miRNAs (five up-regulated and 2 no change miRNAs) and confirmed their expression in GDNF-treated U251 glioma cells using real-time PCR (Fig. 3C, D) . Two up-regulated miRNAs were randomly selected for real-time PCR to confirm their expression levels in GDNF-treated U87 glioma cells (Fig. 3E ).
To further clarify the effect of GDNF on miRNA expression, we used an anti-GDNF antibody to neutralize GDNF secreted by U251 glioma cells and performed real-time PCR to measure the expression of hsa-miR-194-5p and hsa-miR-205-5p. The expression levels of these two miRNAs were significantly decreased after neutralizing GDNF (P < 0.05) (Fig. 3F) . 
Target prediction and function analysis of co-regulated miRNAs
The target genes of these seven up-regulated miRNAs were predicted with miRWalk (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/), which integrates the predictive information of 12 miRNA target prediction databases. If a gene is predicted as target gene by more than 6 databases, these predictions are considered accurate. Next, we selected genes predicted as targets of two or more miRNAs to perform GO and KEGG pathway analyses. The most significant biological processes were GO:0006355 DNA-dependent regulation of transcription, GO:0006350 transcription, GO:0007165 signal transduction, GO:0007275 development, GO:0007155 cell adhesion, and GO:0007049 cell cycle (Fig. 4A) . Similarly, pathway analysis showed that the predicted target genes related to these seven up-regulated miRNAs were involved in axon guidance, MAPK signaling, focal adhesion, Wnt signaling, prostate cancer, and glioma (Fig. 4B) . Ingenuity pathway analysis (IPA) was performed to generate the regulation network of the seven up-regulated miRNAs with relevant mRNAs and regulating factors. Interestingly, the network indicated that hsa-miR-194-5p, hsamiR-152-3p, hsa-miR-205-5p, hsa-miR-183-5p, and hsa-miR-487b-3p co-regulated tumor protein p53 (TP53) and Akt, which play important roles in glioma development (Fig. 5) .
To further evaluate the target prediction results, mRNA levels of TP53, Akt3, serine/ threonine-protein kinase (SIK1) and desmocollin-2 (DSC2) co-targeted by two or more (Fig. 6 ).
Discussion
Our results confirmed the findings in previous studies showing that high GDNF expression promotes malignant glioma cell proliferation and migration [11, 14, 15, 21] . However, the molecular mechanisms underlying these observations remain unclear. Recent reports indicate miRNAs as an important factor, and the abnormal expression of some miRNAs are involved in GDNF-mediated signaling pathways [31] [32] [33] [34] . We tested the hypothesis that GDNF promotes glioma cell proliferation and migration by modulating the expression of specific miRNAs. 
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GDNF significantly increased the expression of seven miRNAs in U251 glioma cells, and this observation was confirmed by real-time PCR and neutralization studies in glioma cells (Fig. 3) . We next searched 1324 genes that were predicted to be targets of 2 or more of these 7 up-regulated miRNAs. The GO analysis identified target genes involved in transcription regulation, signal transduction, cell adhesion, cell cycle, cell differentiation, and anti-apoptosis, all functions closely related to glioma development [38] . Recent studies have reported that precursor N-cadherin and integrin β1 proteins serve as signal transduction molecules in GDNF-induced glioma migration [13, 39] . These cell adhesion molecules are associated with 5 miRNAs, namely hsa-miR-183-5p, hsa-miR-205-5p, hsa-miR-152-3p, hsa-miR-629-5p, and hsa-miR-3609. GDNF may regulate adhesion molecule expression via specific miRNAs to affect signaling cascades in glioma cells. DSC2, a desmosomal cadherin protein, is targeted by hsa-miR-205-5p, hsa-miR-152-3p, and hsa-miR-194-5p, and it was down-regulated in U251 glioma cells treated with GDNF (Fig. 6D) . Reduced DSC2 expression is significantly correlated with higher tumor grading and is a prognostic biomarker for decreased survival in patients with multiple high-grade carcinomas [40] [41] [42] . In addition, we confirmed that GDNF promotes U251 glioma cell proliferation and significantly increases the proportion of cells in the S phase (Fig. 1D) . Phosphorylated cyclin-dependent kinase inhibitor 1B (CDKN1B) can inhibit the conversion from the G1 to S phase [43] , and it is targeted by hsa-miR-152-3p and hsa-miR-194-5p. U2AF homology motif kinase 1 (UHMK1) is a target gene of hsa-miR-183-5p, hsa-miR-205-5p, and hsa-miR-152-3p and can control CDKN1B phosphorylation [44] . Oncostatin M (OSM) targeted by hsa-miR-3609 has been characterized as a potent tumor cell growth inhibitor that induces cell cycle arrest in the G1 phase by increasing p21
Cell Physiol
Cip1/Waf1/ Sdi1 and p27 Kip1 expression in glioma cells [45] . OSMR is one of the heterodimeric receptors for OSM [46] , and it is a target gene of hsa-miR-183-5p, hsa-miR-152-3p, and hsa-miR-487b-3p. Furthermore, transcription factor 7-like 2 (TCF7L2) targeted by hsa-miR-183-5p, hsamiR-194-5p, and hsa-miR-629-5p and cullin-3 (CUL3) targeted by hsa-miR-152-3p and hsamiR-194-5p also regulate G1 arrest [47, 48] . Collectively, our findings suggest that miRNAs influence GDNF-induced glioma cell proliferation via their effects on cell cycle regulatory factors.
KEGG pathways were queries to identify the specific signal pathways including the seven up-regulated miRNA target genes. The results revealed that participate in colorectal cancer, prostate cancer, pancreatic cancer, glioma, and other cancer-related pathways. Among these, MAPK, Wnt, and mammalian target of rapamycin (mTOR) signaling pathways are closely related to glioma occurrence and development [49] . These signaling cascades primarily down-regulate tumor-suppressor genes and up-regulate tumor-causing genes in glioma [11, 15, [50] [51] [52] . Taking tuberous sclerosis complex-1 (TSC1) as an example, it acts as a tumor suppressor in complex with TSC2 to influence cell adhesion, migration, and fate determination in the central nervous system [53] . Deregulation of TSC expression is implicated in ~50% of deaths among children diagnosed with a brain tumor [53] . Moreover, Tsc1 deficiency upregulates mTOR complex 1 activity and accelerates malignant gliomagenesis [54] . mTOR inhibitors have recently been used to treat astrocytomas in patients with TSC [55] [56] [57] . Here we revealed that hsa-miR-183, a contributor of glioma progression [58] , can work with hsamiR-3609 to target Tsc1 gene expressions. SIK1 is another tumor inhibitor that plays a key role in p53/TP53-dependent anoikis and can suppress metastasis [59] . SIK1 is targeted by hsa-miR-152-3p and hsa-miR-629-5p, and our previous mRNA microarray data showed that SIK1 was down-regulated in U251 glioma cells after 24-h incubation with 100 ng/mL GDNF (Fig. 6C) . Previous studies have demonstrated that GDNF can promote glioma cell growth by activating MAPK signaling [11, 50, 60] , which is consistent with our findings. We found that hsa-miR-152-3p, hsa-miR-194-5p, hsa-miR-629-5p, and hsa-miR-3609b all are able to target MAPK, and hsa-miR-152-3p and hsa-miR-194-5p are both concerned with glioma development [61, 62] . In addition, MAP2K, MAP3K, and ATF2, the key factors in the MAPK signaling pathway, are also target genes of hsa-miR-629-5p, hsa-miR-3609, and hsa-miR-183-5p.
The comprehensive functions of the seven differentially expressed miRNAs were evaluated after constructing the regulatory network of differentially expressed miRNAs with mRNAs and other regulatory factors using IPA analysis. TP53 and Akt were at the core of the regulatory network, and they are related to five (hsa-miR-194-5p, hsa-miR-152-3p, hsa-miR-205-5p, hsa-miR-183-5p, and hsa-miR-487b-3p) of the seven miRNAs. These two genes are involved in tumorigenesis, cell cycling, and cell survival, underscoring the importance of these Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry miRNAs in glioma occurrence and development. TP53 is an important tumor suppressor gene, and loss of its function can significantly promote glioma formation and development [63] [64] [65] . A recent study found that hsa-miR-183-5p is involved in pituitary tumor aggressiveness and malignancy via regulation of P53 expression [66] . Its levels were notably higher in glioma tissue compared to normal brain tissue and were significantly positive correlated with tumor size and World Health Organization grade [67] . Our results further demonstrate that GDNF can significantly increase hsa-miR-183-5p expression in glioma cells. Diaz-Rodriguez et al. reported that GDNF and p53 levels were negatively correlated in somatotropinomas [68] , which is consistent with our findings in U251 and U87 glioma cells (Fig. 6A, E) . High GDNF levels may inhibit P53 expression by up-regulating hsa-miR-183-5p to promote glioma development. In addition, bioinformatics analysis revealed that up-regulated hsamiR-152-3p targets TP53 and another tumor suppressor, phosphatase and tensin homolog deleted on chromosome ten (PTEN) [69, 70] ; it is also involved in glioma cell invasion and angiogenesis via neuropilin 2 (NRP-2) and MMP-3 [71] . Tumor protein p53-inducible nuclear protein 1 (TP53INP1) and apoptosis-stimulating of p53 protein 2 (TP53BP2) are the target genes of hsa-miR-205-5p and participate in the regulation of P53 activity [72, 73] . TP53INP1 regulates p53-dependent apoptosis through phosphorylation at Ser46, serving as a co-factor for the putative p53-Ser46 kinase [72] . TP53BP2 can enhance the DNA binding and trans-activation of TP53 on the promoters of pro-apoptotic genes [73] . Moreover, hsamiR-205-5p holds potential as a prognostic indicator for glioma, especially for patients with advanced disease [74] . Akt, also known as PKB or Rac, includes three transcripts (Akt1, Akt2, and Akt3) that play important roles in cell survival and apoptosis. Akt3 is the target gene of hsa-miR-629-5p and hsa-miR-205-5p, and its mRNA expression decreased after GDNF treatment (Fig. 6B) . Recent studies have shown that Akt3 can significantly inhibit the glioma cell aggressiveness and slow down disease progression [75] . Akt3 is mainly expressed in the brain and is crucial for malignant glioma cell viability [76] , which may be the key molecule in MMP13 regulation via IL13 [77] .
Conclusion
We confirmed that glioma cell proliferation and migration are significantly promoted by GDNF, and miRNAs regulate these processes. All significantly differentially expressed miRNAs are involved in cell adhesion and division function, which are closely related to glioma progression. Five significantly highly expressed miRNAs influenced levels of TP53 and Akt, which are involved in tumorigenesis, cell cycling, and cell survival and play an important role in glioma occurrence and development. This suggests that these five miRNAs, especially miR-183, could be useful biological markers for glioma detection. Expression levels of TP53, Akt3, SIK1 and DSC2 co-targeted by two or more up-regulated miRNAs were decreased in GDNF-treated glioma cells. However, these predictions are merely a starting point for studying differentially expressed miRNAs induced by GDNF in glioma cells; the exact functions of these miRNAs remain to be clarified.
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